Georges Elhomsy, MD
Endocrinology, Diabetes & Metabolism · Wichita, KSNPI 1952564908
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 46 manufacturers reported payments, led by Novo Nordisk at 46.4% of the total. Reporting peaked in 2019 at $6,195 and has fallen 73.2% since, to $1,661 in 2025.
Across 540 payments — averaging $25.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$6K
- Amgen$851
- Abbott$627
- Dexcom, Inc.$600
- Recordati_rare_diseases_inc.$468
- Lilly USA, LLC$381
- plus $4K from 40 others
What the payments were for
- Consulting fees$4,50533%
- Speaking & faculty fees$3252%
- Travel & lodging$6825%
- Food & beverage$8,04259%
- Education$1141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,668 in reported general payments places this provider in the 85th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.
See all endocrinology, diabetes & metabolism providers in Kansas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 1,024 | $1,165,391 |
| MounjaroTirzepatide | 812 | $986,210 |
| KorlymMifepristone | 28 | $806,791 |
| Tresiba Flextouch U-200Insulin Degludec | 306 | $355,412 |
| JardianceEmpagliflozin | 293 | $267,412 |
| SomavertPegvisomant | 13 | $210,203 |
| IsturisaOsilodrostat Phosphate | 12 | $192,596 |
| TrulicityDulaglutide | 145 | $150,914 |
| Somatuline DepotLanreotide Acetate | 12 | $126,022 |
| Tresiba Flextouch U-100Insulin Degludec | 202 | $119,540 |
| ProliaDenosumab | 66 | $115,372 |
| Sandostatin Lar DepotOctreotide Acetate,mi-Spheres | 12 | $109,372 |
| FarxigaDapagliflozin Propanediol | 111 | $106,841 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 47 | $73,747 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 105 | $70,737 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6, Novolog | $6,340 | $1,260,9491,151 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $381 | $1,150,8681,001 claims |
| Corcept TherapeuticsKorlym | $265 | $806,79128 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $178 | $282,991309 claims |
| PfizerSomavert | $200 | $210,20313 claims |
| Recordati_rare_diseases_inc.Isturisa | $468 | $192,59612 claims |
| Ipsen Biopharmaceuticals, IncSomatuline Depot | $24 | $126,02212 claims |
| AmgenProlia | $851 | $115,37266 claims |
| NovartisSandostatin Lar Depot | $230 | $109,37212 claims |
| AstraZenecaFarxiga | $191 | $106,841111 claims |
| AbbVieSynthroid | $104 | $56,757763 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $112 | $32,45830 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 50 endocrinology, diabetes & metabolism providers in Kansas.
Other endocrinology, diabetes & metabolism in Wichita
- Dany ZayourWichita$744K
- Rami MortadaWichita$105K
- Sahar HachemWichita$5K
- Youssef HassanWichita$2K
- Ali JamalallailWichita$2K
- Syeda BatoolWichita$156
- Lillian HarstineWichita$12
- Andrew GreenShawnee Mission$322K
- Michael SokolOverland Park$227K
- Sajeev MenonOverland Park$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.